Search

PF-03187207

Based on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to have an increased capacity to reduce high IOP. … The development of abnormally high IOP, due to blockage or malfunction of systems controlling the amount of fluid in the eye, is believed to be one of the principal causes of glaucoma.

Tosylchloramide

It is not stable in the water dissolved form.

Belnacasan

VX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions, as it blocks the hypersensitive response to an inflammatory stimulus.

Neosaxitoxin

Neosaxitoxin is under investigation in clinical trial NCT01786655 (Safety Study of Long-Acting Local Anesthetic).

beta-Hydroxyisovaleric acid

beta-Hydroxyisovaleric acid is under investigation in clinical trial NCT03018496 (Investigating the Effects of Beta-Hydroxy-Beta-Methylbutyrate on Glucose Handling in Older and Younger Men.).

Brentuximab

Brentuximab (SGN-30) is an engineered monoclonal antibody (mAb) that reacts with significant affinity to the CD30 antigen, which is highly expressed on a variety of hematologic malignancies as compared … to on normal cells.

Cynodon dactylon pollen

It can be cutaneously, intradermally and subcutaneously administered to initiate an immune response in case of an allergic reaction.

19-norandrostenedione

After 2005, 19-Norandrostenedione was regulated in the United States as a schedule III controlled substance, as well as banned from use in competitive sports by the World Anti-Doping Agency. … In the body 19-norandrostenedione is rapidly metabolized into [nandrolone], also known as nortestosterone.

Trimethyltetradecylammonium

Aminoethyl nitrate